Dual inhibitors of CDK2 and TRKA kinases: design, synthesis, antiproliferative activity and molecular modeling of novel pyrazolopyrimidine derivatives
Mohamed H. Attia, Deena S. Lasheen, Nermin Samir, Azza T. Taher, Hatem A. Abdel-Aziz, Dalal A. Abou El Ella · 2026
Read Dual inhibitors of CDK2 and TRKA kinases: design, synthesis, antiproliferative activity and molecular modeling of novel pyrazolopyrimidine derivatives by Mohamed H. Attia, Deena S. Lasheen, Nermin Samir, Azza T. Taher, Hatem A. Abdel-Aziz, Dalal A. Abou El Ella (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13579623.txt.
Description
Mohamed Attia and five co-authors built molecules that block two cancer kinases at once, in this 2026 study. One target drives the cell cycle, the other helps tumor cells survive. Twenty-one new compounds in three related families were screened across sixty cancer cell lines from a national panel.
One compound slowed growth in every line. Two others led on the kinase tests, blocking the cycle kinase near a third of a micromolar and the survival kinase far lower. Both also killed brain and blood cancer cells at fair doses while sparing normal cells better than a reference drug. Treated cells stalled before division and died in rising shares. The authors present the pair as leads for dual-target cancer drugs.
Catalog record
| CREATOR | Mohamed H. Attia, Deena S. Lasheen, Nermin Samir, Azza T. Taher, Hatem A. Abdel-Aziz, Dalal A. Abou El Ella |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 70 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |